Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02 Article

Nghiemphu, Phioanh Leia, Ebiana, Victoria Asuquo, Wen, Patrick et al. (2018). Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02 . JOURNAL OF NEURO-ONCOLOGY, 136(1), 79-86. 10.1007/s11060-017-2624-4

Open Access International Collaboration

cited authors

  • Nghiemphu, Phioanh Leia; Ebiana, Victoria Asuquo; Wen, Patrick; Gilbert, Mark; Abrey, Lauren E; Lieberman, F; DeAngelis, Lisa M; Robins, H Ian; Yung, WK Alfred; Chang, Susan; Drappatz, Jan; Mehta, Minesh P; Levin, Victor A; Aldape, Kenneth; Dancey, Janet E; Wright, JJ; Prados, Michael; Kuhn, John; Cloughesy, Timothy F

sustainable development goals

authors

publication date

  • January 1, 2018

webpage

published in

keywords

  • ANTIEPILEPTIC DRUGS
  • BRAIN-TUMOR CONSORTIUM
  • CLINICAL-TRIALS
  • Clinical Neurology
  • Combination study
  • FARNESYLTRANSFERASE INHIBITOR
  • KINASE INHIBITORS
  • LUNG-CANCER THERAPY
  • Life Sciences & Biomedicine
  • MALIGNANT GLIOMA
  • Neurosciences & Neurology
  • Oncology
  • PROTEIN-KINASE
  • RAF KINASE
  • Recurrent GBM
  • Science & Technology
  • Sorafenib
  • TRANSFERASE INHIBITOR R115777
  • Tipifarnib

Digital Object Identifier (DOI)

publisher

  • SPRINGER

start page

  • 79

end page

  • 86

volume

  • 136

issue

  • 1